About Technology Development
UT Southwestern Medical Center has been protecting and licensing intellectual property for more than 40 years. The Office for Technology Development (OTD) was created in 1998 to manage UT Southwestern's technology transfer activities and to facilitate the formation of biomedical companies based on UT Southwestern-developed technologies.
The Office for Technology Development team is comprised of the following groups:
Technology Commercialization manages and markets intellectual property developed by university investigators/inventors.
Cooperative & Sponsored Research drafts, negotiates and executes all non-royalty bearing legal agreements governing intellectual property transferred onto or off of UT Southwestern's campus.
Business Development identifies companies best suited for commercial development of intellectual property.
Venture Development researches technologies suitable for entrepreneurial development and assists in developing startup companies based on those technologies.
Financial Management manages the Office for Technology Development's financial portfolio.
Faculty Liaisons engage with faculty, clinicians and researchers, to facilitate intellectual property disclosures and to breakdown the complexities of the commercialization process.
Exonics Therapeutics, located in Dallas, Texas, is a biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to correct genetic mutations resulting in neuromuscular diseases such as Duchenne muscular dystrophy. While the company's initial focus is on Duchenne, it looks forward to advancing its gene editing platform to additional pediatric indications with significant unmet medical need.
Founded in 2017
Peloton Therapeutics, Inc. is an oncology drug discovery and development company focused on advancing first-in-class small molecule therapies that provide patients suffering from life-threatening diseases with new therapeutic options.
Founded in 2011
OncoNano Medicine, located in Southlake, Texas, is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple, and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. The company’s lead program, ONM-100, targets tumor acidosis to accurately differentiate cancer from healthy tissue for use in surgery.
Founded in 2016
Reata Pharmaceuticals is a biopharmaceutical company based in Irving, Texas. Its mission is to develop novel therapeutics for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.
Founded in 2002
For more information, call the Office for Technology Development at 214-648-1881 or email us. firstname.lastname@example.org